TScan Therapeutics, Inc. TCRX
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.05M | 982.00K | 2.57M | 2.51M | 3.08M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.05M | 982.00K | 2.57M | 2.51M | 3.08M |
| Cost of Revenue | 23.40M | 21.90M | 18.44M | 31.69M | 32.63M |
| Gross Profit | -22.35M | -20.92M | -15.87M | -29.18M | -29.56M |
| SG&A Expenses | 8.14M | 8.22M | 5.99M | 7.87M | 9.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.54M | 30.12M | 24.43M | 39.56M | 41.73M |
| Operating Income | -30.49M | -29.14M | -21.86M | -37.05M | -38.65M |
| Income Before Tax | -30.36M | -28.67M | -22.98M | -35.71M | -36.95M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -30.36M | -28.67M | -22.98M | -35.71M | -36.95M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -30.36M | -28.67M | -22.98M | -35.71M | -36.95M |
| EBIT | -30.49M | -29.14M | -21.86M | -37.05M | -38.65M |
| EBITDA | -29.79M | -28.45M | -21.14M | -36.29M | -37.96M |
| EPS Basic | -0.45 | -0.48 | -0.40 | -0.63 | -0.65 |
| Normalized Basic EPS | -0.28 | -0.30 | -0.23 | -0.39 | -0.41 |
| EPS Diluted | -0.45 | -0.48 | -0.40 | -0.63 | -0.65 |
| Normalized Diluted EPS | -0.28 | -0.30 | -0.23 | -0.39 | -0.41 |
| Average Basic Shares Outstanding | 67.78M | 60.10M | 56.90M | 56.75M | 56.75M |
| Average Diluted Shares Outstanding | 67.78M | 60.10M | 56.90M | 56.75M | 56.75M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |